泌尿生殖器用薬市場：製品、適応症、薬剤タイプ別-2025-2030年の世界予測

泌尿生殖器用薬市場は、2023年に383億米ドルと評価され、2024年には398億3,000万米ドルに達すると予測され、CAGR 4.17％で成長し、2030年には510億1,000万米ドルに達すると予測されています。

泌尿生殖器用薬市場は、主に生殖器系および泌尿器系に影響を及ぼす疾患の治療に使用される医薬品に関係しています。これには、尿路感染症、勃起不全、尿失禁、過活動膀胱、その他の関連疾患の治療薬が含まれます。この市場の必要性は、高齢化やライフスタイルの変化などの要因による泌尿器系疾患の有病率の上昇によって裏付けられています。これらの治療薬の用途は、病院、診療所、在宅ケアなど様々なヘルスケア環境にわたっており、対象となるエンドユーザーは、急性および慢性治療ソリューションを必要とする患者です。主な成長要因としては、より効果的で的を絞った治療法の開発を促進するバイオテクノロジーと医薬品の発展、早期発見を強化する診断ツールの改良、医療費の増大などが挙げられます。

最近の市場機会は、治療効率が高く副作用の少ない個別化医療や生物製剤の採用が増加していることから生まれています。これらを活用することで、企業は個々の患者の遺伝子プロファイルに合わせた医薬品の開発に注力することができます。また、患者のアドヒアランスとモニタリングを強化する技術を統合することで、治療成果を向上させるデジタル・セラピューティクスも有望な分野です。市場拡大を阻む課題としては、新薬の導入を遅らせる厳しい規制当局の承認、研究開発費の高騰、ジェネリック医薬品競争につながる特許切れなどが挙げられます。ヘルスケアシステムがコスト抑制に努めているため、価格圧力と償還の問題がさらに市場の抑制要因を強めています。

技術革新は、ナノ粒子や徐放性製剤などの新しいドラッグデリバリー・システムの探求に軸足を置き、患者のコンプライアンスに対応し、薬効を高めることができます。さらに、希少な泌尿器科疾患におけるアンメットニーズをターゲットにすることで、ニッチ市場の成長機会がもたらされる可能性があります。市場の性質は、継続的な研究開発努力に後押しされ、競争が激しく、日進月歩です。戦略的パートナーシップや共同研究は、リソースを統合し新薬開発を早める方法を提供する可能性があります。結論として、泌尿生殖器用薬市場において持続的な成長と競争上の優位性を確保するためには、研究開発への明確な焦点を維持し、規制の更新に適応し、技術の進歩に対応することが重要です。

市場力学：急速に進化する泌尿生殖器用薬市場の主要市場インサイトを公開

泌尿生殖器用薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 泌尿生殖器疾患の有病率の増加
  • パイプライン医薬品の増加
  • 尿失禁やインポテンツに対する懸念の高まり
• 市場抑制要因
  • 市場における偽造品やジェネリック医薬品の存在
• 市場機会
  • 製薬企業による共同研究開発の取り組み
  • 治療改善のためのヘルスケアへの投資拡大
• 市場の課題
  • 服薬コンプライアンスの欠如
  • 継続的な特許切れ

ポーターの5つの力泌尿生殖器用薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：泌尿生殖器用薬市場における外部からの影響の把握

外部マクロ環境要因は、泌尿生殖器用薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析泌尿生殖器用薬市場における競合情勢の把握

泌尿生殖器用薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス泌尿生殖器用薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、泌尿生殖器用薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨泌尿生殖器用薬市場における成功への道筋を描く

泌尿生殖器用薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 泌尿生殖器疾患の罹患率の増加
    • パイプライン医薬品の増加
    • 尿失禁とインポテンスに対する懸念の高まり
  • 抑制要因
    • 市場における偽造医薬品およびジェネリック医薬品の入手可能性
  • 機会
    • 製薬企業による共同研究開発の取り組み
    • 治療の改善に向けたヘルスケアへの投資増加
  • 課題
    • 服薬遵守の欠如
    • 特許の継続的な失効
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 泌尿生殖器用薬市場：製品別

• 抗感染薬
• 婦人科
• ホルモン療法
• 泌尿器科

第7章 泌尿生殖器用薬市場適応症別

• 前立腺肥大症
• 膀胱がん
• 子宮頸がん
• 勃起不全
• 血尿
• 間質性膀胱炎
• 卵巣がん
• 前立腺がん
• 腎臓がん
• 性感染症
• 尿失禁と過活動膀胱
• 尿路感染症

第8章 泌尿生殖器用薬市場薬の種類別

• ホルモン療法
• インポテンス治療薬
• 尿路鎮痙薬
• 尿 pH調整剤
• 子宮弛緩剤
• 子宮刺激剤

第9章 南北アメリカの泌尿生殖器用薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の泌尿生殖器用薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの泌尿生殖器用薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Asieris Pharmaceuticals
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Cipla Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• The Bristol Myers Squibb Company

LIST OF FIGURES

• FIGURE 1. GENITOURINARY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. GENITOURINARY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GENITOURINARY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GENITOURINARY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGICALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HEMATURIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY INCONTINENCE & OVERACTIVE BLADDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IMPOTENCE AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY ANTISPASMODICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY PH MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UTERINE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UTERINE STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. CANADA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. CHINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. CHINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. INDIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 71. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 83. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 95. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 96. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 99. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 102. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 105. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 108. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 111. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. ITALY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. ITALY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. ITALY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 120. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 123. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. POLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. POLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. POLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 129. QATAR GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. QATAR GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. QATAR GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 132. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 141. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 144. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 147. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 150. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 153. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 154. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 156. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 159. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 160. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Genitourinary Drugs Market was valued at USD 38.30 billion in 2023, expected to reach USD 39.83 billion in 2024, and is projected to grow at a CAGR of 4.17%, to USD 51.01 billion by 2030.

The genitourinary drugs market is primarily concerned with medications used to treat disorders affecting the genital and urinary systems. This encompasses drugs for urinary tract infections, erectile dysfunction, urinary incontinence, overactive bladder, and other related conditions. The necessity of this market is underscored by the rising prevalence of genitourinary disorders due to factors such as aging populations and lifestyle changes. The application of these drugs spans across various healthcare settings, including hospitals, clinics, and homecare, with targeted end-users being patients requiring both acute and chronic treatment solutions. Key growth influencers include advances in biotechnology and pharmaceuticals, which facilitate the development of more effective and targeted therapies, improved diagnostic tools enhancing early detection, and growing healthcare expenditure.

Recent opportunities in the market emerge from the increasing adoption of personalized medicine and biologics, which possess high therapeutic efficiency and fewer side effects. Leveraging these, companies can focus on developing drugs tailored to individual patient genetic profiles. Another promising area lies in digital therapeutics, integrating technology for enhanced patient adherence and monitoring, thereby improving treatment outcomes. Challenges limiting market expansion include stringent regulatory approvals that delay the introduction of new drugs, high R&D costs, and patent expirations leading to generic competition. Pricing pressures and reimbursement issues further compound market constraints as healthcare systems strive to control costs.

Innovation can pivot towards exploring novel drug delivery systems such as nanoparticles and sustained-release formulations, catering to patient compliance and enhancing drug efficacy. Additionally, targeting unmet needs in rare urological disorders could yield niche market growth opportunities. The market's nature is distinctly competitive and fast-evolving, driven by continuous research and development efforts. Strategic partnerships and collaborations could offer ways to consolidate resources and hasten new drug development. In conclusion, maintaining a clear focus on R&D, adaptation to regulatory updates, and responsiveness to technological advances are critical for sustained growth and competitive advantage in the genitourinary drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genitourinary Drugs Market

The Genitourinary Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of genitourinary disorders
  • Rising number of pipeline drugs
  • Growing concerns about urinary incontinence and impotence
• Market Restraints
  • Availability of counterfeit and generics drugs in the market
• Market Opportunities
  • Collaborative R&D efforts by the pharma companies
  • Growing investment in healthcare for improved treatments
• Market Challenges
  • Lack of compliance to medication
  • Continual patent expirations

Porter's Five Forces: A Strategic Tool for Navigating the Genitourinary Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genitourinary Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genitourinary Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genitourinary Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genitourinary Drugs Market

A detailed market share analysis in the Genitourinary Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genitourinary Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genitourinary Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genitourinary Drugs Market

A strategic analysis of the Genitourinary Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genitourinary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asieris Pharmaceuticals, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and The Bristol Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Genitourinary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Anti-infectives, Gynecological, Hormonal Therapy, and Urologicals.
• Based on Indication, market is studied across Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer, Erectile Dysfunction, Hematuria, Interstitial Cystitis, Ovarian Cancer, Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Urinary Incontinence & Overactive Bladder, and Urinary Tract Infections.
• Based on Drug Type, market is studied across Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, and Uterine Stimulants.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of genitourinary disorders
    • 5.1.1.2. Rising number of pipeline drugs
    • 5.1.1.3. Growing concerns about urinary incontinence and impotence
  • 5.1.2. Restraints
    • 5.1.2.1. Availability of counterfeit and generics drugs in the market
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative R&D efforts by the pharma companies
    • 5.1.3.2. Growing investment in healthcare for improved treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of compliance to medication
    • 5.1.4.2. Continual patent expirations
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Genitourinary Drugs Market, by Product

• 6.1. Introduction
• 6.2. Anti-infectives
• 6.3. Gynecological
• 6.4. Hormonal Therapy
• 6.5. Urologicals

7. Genitourinary Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Benign Prostatic Hyperplasia
• 7.3. Bladder Cancer
• 7.4. Cervical Cancer
• 7.5. Erectile Dysfunction
• 7.6. Hematuria
• 7.7. Interstitial Cystitis
• 7.8. Ovarian Cancer
• 7.9. Prostate Cancer
• 7.10. Renal Cancer
• 7.11. Sexually Transmitted Diseases
• 7.12. Urinary Incontinence & Overactive Bladder
• 7.13. Urinary Tract Infections

8. Genitourinary Drugs Market, by Drug Type

• 8.1. Introduction
• 8.2. Hormonal Therapy
• 8.3. Impotence Agents
• 8.4. Urinary Antispasmodics
• 8.5. Urinary pH Modifiers
• 8.6. Uterine Relaxants
• 8.7. Uterine Stimulants

9. Americas Genitourinary Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Genitourinary Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Genitourinary Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Asieris Pharmaceuticals
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Bayer AG
• 7. Cipla Inc.
• 8. Eli Lilly and Company
• 9. F. Hoffmann-La Roche Ltd.
• 10. GlaxoSmithKline PLC
• 11. Johnson & Johnson Services, Inc.
• 12. Merck & Co., Inc.
• 13. Novartis AG
• 14. Pfizer, Inc.
• 15. Teva Pharmaceutical Industries Ltd.
• 16. The Bristol Myers Squibb Company